Xoma Corp. (Nasdaq: XOMA) Rises on Proof-of-Concept

Xoma Corporation – Nasdaq: XOMA

Xoma Corporation announced, after hours, that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery. Berkley, CA-based Xoma is up almost 10%, on heavy volumes, in the after-hours market on the news. The regular session ended with XOMA at $4.29 and has reached $4.83 in the after-hours session.

XOMA Corporation develops therapeutic antibodies. The Company’s product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA’s scientific research has produced a portfolio of endocrine assets, each of which has the opportunity to address multiple indications.

Eric P. Brass, M.D., Ph.D. stated “These data clearly demonstrate that a single-dose of 358 results in predictable and reproducible pharmacokinetics and meaningful improvements in glucose concentrations. The Company can now assess, in follow-on studies, the consistency and magnitude of 358’s effect through multi-dose protocols to yield sustained steady-state drug exposure in the target populations.”

Xoma Corporation sales have been erratic but in 2015 Xoma posted their best results since 2011 with a figure of $$55.4 million. EPS for XOMA has been negative for the past five years, but again the smallest loss was posted in 2015 with a loss figure of $3.50. Four firms follow Xoma and all rate the shares as a “Hold” with a consensus price target of $9.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

NetScout Systems (Nasdaq: NTCT) Beats Estimates and Shares Rise

Netscout Systems, Inc. – Nasdaq: NTCT

Shares of NetScout are higher after earnings beat street estimates. NTCT, traded on the Nasdaq, was expected to earn $0.55 EPS but NetScout came in at $0.60. The firm also reported a net income of $21.2 million after reporting a loss for the same period last year. NetScout develops, sells, and services application and network performance management products and solutions.

Anil Singhal, NETSCOUT’s president and CEO. “While the service provider spending environment remains muted, we are seeing momentum build for our newest offerings, including the software version of the InfiniStreamNG, our next-generation, real-time information platform. We have continued to execute well on our development roadmaps that align with a range of exciting opportunities spanning each of our major product areas and customer segments globally. As we move forward, we are focused on achieving our fiscal year 2017 financial, product and operational objectives while also setting the stage for further progress that can drive shareholder value in the next fiscal year.”

NetScout sales have increased year-on-year with the largest increase in 2016 when they reported sales of $955.4 million. EPS for NTCT had also increased year-on-year until 2016 when NTCT posted a loss of $$0.35. Eight firms follow NetScout Systems. Four rate NTCT shares as a “Strong Buy” and four rate the shares as a “Hold”. Their consensus price estimate for NTCT shares is $31.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/31/2017
Ticker Symbol NTCT
Last Price a/o 3:59 PM EST  $                    33.25
Average Volume                    651,860
Market Cap (mlns)  $              2,880.00
Sales (mlns) $1,130.00
Shares Outstanding (mlns) 91.57
Share Float (mlns) 87.78
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 10.08%
Short Interest Ratio 13.57
Quarterly Return 15.20%
YTD Return -0.16%
Year Return 45.94%

Roadrunner Transportation Systems (Nasdaq RRTS) Plunges After Accounting Error Admission

Roadrunner Transportation Systems, Inc. – Nasdaq: RRTS

Roadrunner Transportation Systems shares are down over 30% on news that the company has discovered accounting errors that could total between $20 – $25 million. RRTS is traded on the Nasdaq and volumes are extremely heavy.

From the press release: “Roadrunner Transportation Systems, Inc., a leading asset-light transportation and logistics service provider, announced today that on January 27, 2017 its Audit Committee, after considering the recommendation of management, concluded that, as a result of the information obtained to date in connection with an ongoing investigation, the following financial statements and associated reports of Roadrunner’s independent registered public accounting firm, Deloitte & Touche LLP, previously filed with the Securities and Exchange Commission (“SEC”) should no longer be relied upon.” The press release continues to identify financial statements and dates. You can read the release here.

Roadrunner Transportation Systems, Inc. is a leading asset-light transportation and logistics services provider offering a full suite of solutions, including customized and expedited less-than-truckload, truckload and logistics, global solutions, intermodal, brokerage, freight consolidation, inventory management, and domestic and international air.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Bellicum Pharmaceuticals (Nasdaq: BLCM) Shares React Positively to New CEO

Bellicum Pharmaceuticals, Inc. – Nasdaq: BLCM

Today a new CEO was appointed to lead Bellicum Pharmaceuticals and shares, traded on the Nasdaq under ticker BLCM, reacted favorably – rising over 8%. BLCM had been trading over $30 in early 2015, but have been trading under $14 for the past few weeks. Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for hematological cancers and solid tumors, as well as orphan inherited blood diseases.

Rick Fair is the new President and Chief Executive Officer, and as a member of the Board of Directors, the appointment is effective immediately. Mr. Fair joins Bellicum from Genentech/Roche, where he was Senior Vice President, Head of Oncology Global Product Strategy, and brings a record of results in global, strategic and operational roles to Bellicum. Mr. Fair succeeds Tom Farrell, who will serve as an advisor to the Company during the transition.

Sales for Bellicum dropped significantly from 2014 to 2015 – $1.8 million to $300,000. However, EPS for BLSM did improve over the same time period. In 2014 BLCM experienced an EPS loss of $3.30 and in 2015 the EPS loss narrowed to $1.84. Six firms follow Bellicum Pharmaceuticals. Five rate BLCM as a “Strong Buy” and one rates the shares as a “Buy”. The consensus price target for BLCM is $30.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/31/2017
Ticker Symbol BLCM
Last Price a/o 1:18 PM EST  $                    12.71
Average Volume                    323,900
Market Cap (mlns)  $                  321.68
Sales (mlns) $0.30
Shares Outstanding (mlns) 27.1
Share Float (mlns) 22.79
Shortable Yes
Optionable Yes
Inside Ownership 1.10%
Short Float 15.21%
Short Interest Ratio 10.7
Quarterly Return -29.43%
YTD Return -12.85%
Year Return 5.04%

Avid Technologies (Nasdaq: AVID) Up on China Partnership

Avid Technology, Inc. – Nasdaq: AVID

Avid Technology announced today that they have entered into a partnership with their long-time partner in China, Beijing Jetsen Technology. The agreement makes Jetsen the exclusive (master) distributor in Greater China of Avid’s comprehensive tools and workflow solutions for creating, distributing and optimizing media. The news has sent AVID shares, traded on the Nasdaq, up 10% in early trading on heavy volumes.

Jetsen will distribute all Avid products and solutions in Greater China, including mainland China, Hong Kong, Macau and Taiwan, continuing to work closely and directly with Avid’s existing reseller network in the region. Supporting Avid’s strategies for the Greater China market, the agreement with Jetsen enables Avid to deliver on its commitment to providing its client community the most flexible deployment models, licensing options and commercial structures with future cloud and enterprise offerings for the region, as well as more localized and tailored solutions.

Since 2011, Avid Technologies have seen negative growth in both EPS and reported sales. In 2011 AVID sales were $766.9 million. That figure has decreased year-on-year and in 2015 AVID sales were $505.6 million. EPS for AVID shares a similar history – $4.23 in 2011 with decreasing EPS each year and $$0.06 EPS for AVID shareholders in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Dimension Therapeutics (Nasdaq: DMTX) Plunge on Interim Results

Dimension Therapeutics, Inc. – Nasdaq: DMTX

Investors are punishing shares of Dimension Therapeutics on the back of the company announcing interim results of their Phase 1 and 2 clinical trials. Dimension Therapeutics trades on the Nasdaq under ticker symbol DMTX. DMTX shares closed the regular session on Monday at $4.25 but dropped to $2.70 in pre-market trading Tuesday and a regular session low of $2.15.

Dimension’s programs address unmet medical needs for patients living with hemophilia and rare diseases associated with the liver. The Company’s lead program in hemophilia B is currently in phase I/II clinical testing. Dimension Therapeutic is also advancing programs through preclinical testing to address hemophilia A in collaboration with Bayer HealthCare and for patients living with ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa).

Dimension Therapeutic sales increased from $2.8 million in 2014 to $7.8 million in 2015. EPS for DMTX increased losses year-on-year – -$0.52 in 2014 and -$4.41 in 2015. Four firms follow DMTX with three rating shares as a “Strong Buy” and one rating DMTX as a “Hold”. Their consensus price target is $12.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Momenta Pharmaceuticals (Nasdaq: MNTA) Jumps After Hours on Teva (NYSE: TEVA) Patent Loss

Momenta Pharmaceuticals, Inc. – Nasdaq: MNTA

A U.S. Court invalidated patents granted to Teva Pharmaceuticals (NYSE: TEVA) for their multiple sclerosis drug Copaxone. That news sent shares of Momenta Pharmaceuticals (Nasdaq: MNTA) up over 8% in after-hours trading. In 2015, Momenta and Sandoz received FDA approval for their generic version of Copaxone. Reports are that Copaxone annually generates $4 billion in revenue for TEVA and that this court ruling could create a $1.2 Billion market for the generic version.

Cambridge, MA-based Momenta develops complex pharmaceutical products. The company utilizes proprietary technology-based methods to develop generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discover and develop of therapeutics for autoimmune indications.

Reported sales and EPS have been increasing for MNTA since 2013 when Momenta reported $35.5 million and -$2.13 respectively. In 2015 MNTA experienced a loss of $1.32 EPS on sales of $89.7 million. Nine firms follow Momenta Pharmaceuticals. Six rate MNTA shares as a “Strong Buy”, two rate the shares as a “Hold”. And one rates MNTA as a “Sell”. The consensus price target for MNTA is $18.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

werner Enterprises (Nasdaq: WERN) Beats Estimates

Werner Enterprises, Inc. – Nasdaq: WERN

Shares of Werner Enterprises closed the regular session at $27.80 but rose to $30.35 on the back of earnings news that beat street estimates. WERN, traded on the Nasdaq, benefitted from an earnings news that its net income had come in at $0.30/share when estimate averages were for $0.26 – revenues beat street estimates by $10 million at $$518.8 million.

Werner Enterprises, Inc., founded in 1956, is a transportation and logistics company, with coverage throughout North America, Asia, Europe, South America, Africa and Australia. Werner maintains its global headquarters in Omaha, Nebraska and maintains offices in the United States, Canada, Mexico, China and Australia. Werner is among the five largest truckload carriers in the United States, with a portfolio of transportation services that includes dedicated van, temperature-controlled and flatbed; medium-to-long-haul, regional and local van; and expedited services. Werner Logistics’ portfolio includes freight management, truck brokerage, intermodal and international services. International services are provided through Werner’s domestic and global subsidiary companies and include ocean, air and ground transportation; freight forwarding; and customs brokerage.

WERN sales have been steady over the past five years – about $2 Billion annually. EPS for WERN has also been positive and growing since 2013. In 2015 WERN EPS was $1.72. Thirteen firms follow WERN. Two rate the shares a “Buy”, nine rate WERN a “Hold”, one rates the shares an “Underperform”, and one rates WERN as a “Sell”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/30/2017
Ticker Symbol WERN
Last Price a/o 7:57 PM EST  $                    29.40
Average Volume 834,230
Market Cap (mlns)  $              2,000.00
Sales (mlns) $2,020.00
Shares Outstanding (mlns) 72.06
Share Float (mlns) 45.78
Shortable Yes
Optionable Yes
Inside Ownership 0.70%
Short Float 12.98%
Short Interest Ratio 7.12
Quarterly Return 13.49%
YTD Return 3.15%
Year Return 16.22%

Sanmina Corp (Nasdaq: SANM) Announces Earnings and Shares Rise

Sanmina Corporation – Nasdaq: SANM

Shares of Sanmina Corporation have trade in the after-market over 7% higher due to a favorable earnings release. For the first fiscal quarter ended December 31, 2016 Revenue for the first quarter was $1.72 billion, compared to $1.67 billion in the prior quarter and $1.53 billion for the same period of fiscal 2016. GAAP operating income in the first quarter was $58.7 million or 3.4 percent of revenue, compared to $54.1 million or 3.5 percent of revenue for the first quarter fiscal 2016. GAAP net income in the first quarter was $44.9 million, compared to $27.1 million for the same period a year ago.  GAAP diluted earnings per share were $0.58, compared to $0.33 in the first quarter of fiscal 2016.

San Jose, CA-based Samina Corporation trades on the Nasdaq under ticker SANM. Sanmina provides end-to-end design, manufacturing and logistics solutions, delivering products and support to Original Equipment Manufacturers (OEMs) primarily in the communications networks, computing and storage, medical, defense and aerospace, industrial and semiconductor, multimedia, automotive and clean technology sectors.

SANM is trading well above the analyst consensus price target of $31. Four firms follow SANM and one rates the shares as a “Strong Buy”, one rates the shares as a “Buy”, and two rate SANM as a “Hold”. Reported sales for SANM have been relatively consistent and in 2015 Sanmina reported sales were $6.48 Billion. EPS for SANM was $4.61 in 2014 and $2.50 in 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/30/2017
Ticker Symbol SANM
Last Price a/o 4:20 PM EST  $                    39.85
Average Volume 252,560
Market Cap (mlns)  $              2,730.00
Sales (mlns) $6,480.00
Shares Outstanding (mlns) 74.27
Share Float (mlns) 72.74
Shortable Yes
Optionable Yes
Inside Ownership 1.40%
Short Float 1.92%
Short Interest Ratio 2.65
Quarterly Return 25.17%
YTD Return 0.41%
Year Return 102.31%

Evok Pharma (Nasdaq: EVOK) Rises on Analyst Upgrade

Evok Pharma, Inc. – Nasdaq: EVOK

An analyst upgrade and positive social forum chatter of technical chart characteristics are pushing up shares of Evok Pharma – traded on the Nasdaq under ticker EVOK. Volumes are heavy. EVOK ended Friday at $2.48 and the shares are now trading over 10% higher in mid-afternoon action.

Solana Beach, CA-based Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by pharmaceutical executives with a track record of acquiring, developing, registering, and marketing pharmaceutical products in the US. Evoke’s lead product candidate, EVK-001, is in late stage clinical testing. The product is intended for the treatment of diabetic gastroparesis.

EPS for EVOK has been negative for the past five years. In 2014 EVOK shares lost $2.20 per share and in 2015 lost $1.87. There are no reported sales for EVOK. Two analysts rate EVOK as a “Strong Buy” one rates the shares a “Buy”, one rates EVOK a “Hold”, and one rates EVOK at a “Sell”. Their consensus price target is $6.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/30/2017
Ticker Symbol EVOK
Last Price a/o 3:32 PM EST  $                      2.77
Average Volume 974,460
Market Cap (mlns)  $                    30.60
Sales (mlns)
Shares Outstanding (mlns) 12.34
Share Float (mlns) 16.45
Shortable Yes
Optionable No
Inside Ownership 32.37%
Short Float 16.45%
Short Interest Ratio 1.6
Quarterly Return 40.11%
YTD Return 22.77%
Year Return -19.22%